Cervical dystonia (CD), is a rare neurological disorder that mostly affects middle-aged adults, with an average age of symptom onset of 50 years. Given the rarity of the condition and symptomatic similarities with other neurological conditions, CD is often misdiagnosed, thereby delaying appropriate treatment. The CD market is generally well served by several marketed botulinum toxins ([BoNTs]; e.g., AbbVie / Allergan’s Botox), which comprise the current standard of care in CD treatment in the United States, EU5, and China. Owing to the clinical benefits provided by entrenched BoNTs, the CD pipeline is relatively sparse and lacks variation / novelty but does portend the potential launch of biosimilars in future. For current and emerging players in this space, understanding the drivers, limiters, unmet needs, and remaining opportunities in this competitive market will be critical.
Product Description: Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geographies: United States, EU5, China.
Primary research: 8 interviews with neurologists in February 2022.
Key companies covered: AbbVie, Ipsen, Merz Pharma, Supernus, Revance Therapeutics, Aeon Biopharma
Key drugs covered: Botox, Dysport, Xeomin, Myobloc, daxibotulinumtoxinA (DAXI, RT-002), ABP-450, onabotulinumtoxinA biosimilar